Lv63
2750 积分 2022-09-27 加入
Elacestrant: First Approval
15天前
已完结
Elacestrant: a new FDA-approved SERD for the treatment of breast cancer
15天前
已完结
Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist
15天前
已完结
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer
15天前
已完结
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
15天前
已完结
General access to cubanes as benzene bioisosteres
1个月前
已完结
Cyclin E1 as a driver of oncogenesis; high grade serous ovarian cancer as an exemplar
1个月前
已完结
Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy
1个月前
已完结
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
1个月前
已完结
Disulfide-Catalyzed Iodination of Electron-Rich Aromatic Compounds
2个月前
已完结
皖公网安备34019202002308
